Sanofi-aventis Advances Diabetes Pipeline

By Staff Editor

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 2 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1362     ISSN: 1756-7874

Section: Licensing



Sanofi-aventis has agreed to pay up to US$375 M to Metabolex to license a novel oral therapy in Phase II development for the treatment of type 2 diabetes, MBX-2982...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details